N M Scheinin

Summary

Affiliation: University of Turku
Country: Finland

Publications

  1. ncbi request reprint Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls
    N M Scheinin
    Turku PET Centre, FIN 20521 Turku, Finland
    Neurology 73:1186-92. 2009
  2. ncbi request reprint Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease
    Noora M Scheinin
    Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland
    Q J Nucl Med Mol Imaging 55:265-79. 2011
  3. doi request reprint Early detection of Alzheimer disease: ¹¹C-PiB PET in twins discordant for cognitive impairment
    N M Scheinin
    Turku PET Centre, University of Turku, Turku, Finland
    Neurology 77:453-60. 2011
  4. doi request reprint [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment
    A Bruck
    Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
    Eur J Nucl Med Mol Imaging 40:1567-72. 2013
  5. ncbi request reprint Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI
    N M Kemppainen
    Turku PET Centre, University of Turku, P O Box 52, 20521, Turku, Finland
    Eur J Nucl Med Mol Imaging 41:283-9. 2014

Collaborators

  • I Raiha
  • J O Rinne
  • J Kaprio
  • N M Kemppainen
  • R Parkkola
  • J Koivunen
  • K NAgren
  • A Bruck
  • J T Toivonen
  • M Karrasch
  • J Rokka
  • J Johansson
  • J R Virta
  • H Helenius
  • M Viitanen
  • S Helin
  • J Koikkalainen

Detail Information

Publications5

  1. ncbi request reprint Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls
    N M Scheinin
    Turku PET Centre, FIN 20521 Turku, Finland
    Neurology 73:1186-92. 2009
    ..We investigated the brain uptake of the amyloid ligand (11)C-labeled Pittsburgh compound B ([(11)C]PIB) and volumetric brain changes over a 2-year follow-up in patients with AD and in aged healthy controls...
  2. ncbi request reprint Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease
    Noora M Scheinin
    Turku PET Centre, University of Turku, Turku University Hospital, Turku, Finland
    Q J Nucl Med Mol Imaging 55:265-79. 2011
    ..This article aims to review the motives, prerequisites, potential, and challenges of using amyloid imaging as a surrogate marker in clinical therapeutic trials in AD...
  3. doi request reprint Early detection of Alzheimer disease: ¹¹C-PiB PET in twins discordant for cognitive impairment
    N M Scheinin
    Turku PET Centre, University of Turku, Turku, Finland
    Neurology 77:453-60. 2011
    ..The aim of this study was to investigate whether cognitively preserved monozygotic or dizygotic cotwins of persons with Alzheimer disease (AD) exhibit increased brain amyloid accumulation...
  4. doi request reprint [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment
    A Bruck
    Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland
    Eur J Nucl Med Mol Imaging 40:1567-72. 2013
    ..The aim of this study was to compare the prognostic ability of [(11)C]PIB PET, [(18)F]FDG PET and quantitative hippocampal volumes measured with MR imaging in predicting conversion to AD in patients with MCI...
  5. ncbi request reprint Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI
    N M Kemppainen
    Turku PET Centre, University of Turku, P O Box 52, 20521, Turku, Finland
    Eur J Nucl Med Mol Imaging 41:283-9. 2014
    ..The aim of this study was to evaluate the longitudinal changes in [(11)C]PIB uptake in mild cognitive impairment (MCI) and Alzheimer's disease (AD) over a long-term follow-up...